Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
| 대상 질환 | Cirrhosis, Hepatocellular Carcinoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | National Cancer Institute (NCI) |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 52 명 |
| 중재(약물) | Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration |
| 시작일 | 2017년 6월 21일 |
| 완료일 | 2023년 5월 3일 |
| 결과 공개일 | 2025년 4월 15일 |
요약
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Change in Serum AFP-L3%
| Group I (Simvastatin) | 0.24 ± 1.00 percent |
|---|---|
| Group II (Placebo) | -0.04 ± 0.11 percent |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)